Sources

9 Total Sources

Samsung Biologics Offers $1.8 Billion for PolyPeptide to Expand Into GLP-1 Peptide Drugs

Left60%

Center20%

Right20%

Samsung Biologics Offers $1.8 Billion for Switzerland's PolyPeptide Group

Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide | Reuters

Korea Economic Daily1d ago

Samsung Biologics to buy PolyPeptide for $1.9 bn in Korea's biggest pharma deal - KED Global

Tech in Asia1d ago

Samsung Biologics to acquire PolyPeptide for $1.8b

🇰🇷 🇨🇭 BREAKING: Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal. The acquisition is the largest biopharmaceutical M&A deal in the country's history… | Ashwin Binwani

코리아타임스1d ago

Samsung Biologics to acquire PolyPeptide for $1.8 bil. - The Korea Times

Bloomberg1d ago

Samsung Biologics to Acquire PolyPeptide in $1.8 Billion All-Cash Deal - Bloomberg

Nikkei Asia1d ago

Samsung Biologics to launch $1.8 bn bid for Swiss PolyPeptide - Nikkei Asia

finance.biggo.com1d ago

Samsung Biologics to Acquire Swiss Peptide CDMO for approximately $1.8 Billion, Targeting Obesity Drug Market — BigGo Finance